In acute myeloid leukemia (AML), FLT3 is a genetic mutation that can be acquired later in the disease. FLT3 is also a genetic mutation responsible for the disease's pathogenesis. It can also develop later if the disease is not controlled. There are two important implications of FLT3 positivity in AML:

The presence of FLT3 in AML puts the patient in a high-risk group. In this case, stem cell transplantation is required.

Smart drugs are available that can correct the AML FLT3 mutation. In addition to standard chemotherapy, these smart drugs that correct the AML FLT3 mutation are given both in first-line treatment and in subsequent consolidation therapies.